Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3‐L1 preadipocytes

Zhe Zhao,Fengying Gong,Lian Duan,Xiaorui Lv,Haijie Wu,Yan Tang,Huijuan Zhu,Xiaoguang Chen
DOI: https://doi.org/10.1111/bcpt.13762
2022-06-17
Abstract:Somatostatin and its analogues, known as somatostatin receptor ligands (SRLs), have been reported to attenuate weight gain in some clinical settings. However, their direct effects on preadipocytes are barely investigated. Therefore, this study aimed to evaluate the influence of SRLs on preadipocytes and to further explore the potential mechanisms. Cell Counting Kit‐8 assay, Oil Red O staining, triglyceride contents measurements, qPCR, and western blot were used to investigate the effects of SRLs on preadipocytes. We found that three SRLs (octreotide, TT232, and pasireotide) inhibited cell viability after 8‐48 h but not 4 h. Further western blot results showed that they significantly suppressed activation of PI3K/Akt pathway. Besides, lipid accumulation was also significantly inhibited by these SRLs. Moreover, mRNA levels of some critical adipogenic markers, including Pparg, Cebpa, Fasn, Fabp4, Acaca, and Lpl, were downregulated by the treatments of all these SRLs. Consistently, the protein expression of PPARγ, C/EBPα, and FAS were also suppressed by SRLs. SRLs inhibit the proliferation and lipogenesis in preadipocytes. Their inhibitory effects on cell proliferation may be mediated by the downregulated PI3K/Akt pathway, and the suppressive actions on lipogenesis may be related to the decreased PPARγ and C/EBPα expression.
pharmacology & pharmacy,toxicology
What problem does this paper attempt to address?